In both cases, the FREM2 RNA expression level in TCGA cohorts was lower, i.e., 1.7 TPM for glioblastoma and 0.1 TPM for breast invasive carcinoma compared to the FREM2 RNA expression level in the corresponding experimental validation cohorts. Here, FREM2 is linked to glioblastoma.